PKD Awareness Day 2026: Insights on the Latest ADPKD KDIGO Guidelines

ADPKD Guidelines Impact

Autosomal dominant polycystic kidney disease (ADPKD) affects roughly 12 million people globally, forming cysts that enlarge kidneys and impair function over decades. The release of KDIGO's first ADPKD-specific guidelines in January 2025 responds to advances in genetics and therapies, updating practices last shaped by fragmented regional advice. This shift comes as incidence data from 2024 registries show ADPKD accounting for 5-10% of kidney failure cases, with half of patients reaching end-stage by age 60.

Recent changes stem from trials like TEMPO and REPRISE, validating tolvaptan for high-risk cases, alongside CRISPR experiments in 2025 targeting PKD1 mutations. These developments underscore urgency: without intervention, cysts can double kidney volume every few years, spiking hypertension risks and straining healthcare systems. In the US, annual dialysis costs for ADPKD patients hit $100,000 per person, amplifying economic pressures amid aging populations.

Stakes are concrete—guidelines push for Mayo Clinic imaging classification to flag rapid progressors by age 30, enabling early tolvaptan use that cuts volume growth by 49%. Deadlines loom with genetic screening windows closing post-symptom onset, while inaction raises rupture risks, with 2025 data linking untreated cases to 15% higher aneurysm rates. Consequences include transplant waits averaging 3-5 years, with 2026 projections estimating 200,000 new global diagnoses.

Non-obvious angles include stakeholder frictions: pharma pushes tolvaptan despite 5% liver toxicity dropout rates in trials, while nephrologists debate SGLT2 inhibitors, excluded from major studies but showing preclinical promise. Trade-offs surface in pediatric care, where early ultrasound risks anxiety without proven benefits, versus delayed detection missing hypertension windows. Surprising 2025 findings reveal lifestyle factors like high-salt diets accelerating progression by 20%, often overlooked in genetic-focused narratives.